0 CHECKOUT

Retinal Degeneration - Pipeline Review, H1 2015

  • ID: 3293099
  • May 2015
  • 82 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Aprogen, Inc.
  • BBB Therapeutics B.V.
  • Bionature E.A. Ltd.
  • Biovista Inc.
  • GenSight Biologics SA
  • SanBio, Inc.
  • MORE

Retinal Degeneration - Pipeline Review, H1 2015

Summary

This, ‘Retinal Degeneration - Pipeline Review, H1 2015’, provides an overview of the Retinal Degeneration’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Degeneration and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aprogen, Inc.
  • BBB Therapeutics B.V.
  • Bionature E.A. Ltd.
  • Biovista Inc.
  • GenSight Biologics SA
  • SanBio, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Retinal Degeneration Overview
Therapeutics Development
Pipeline Products for Retinal Degeneration - Overview
Pipeline Products for Retinal Degeneration - Comparative Analysis
Retinal Degeneration - Therapeutics under Development by Companies
Retinal Degeneration - Therapeutics under Investigation by Universities/Institutes
Retinal Degeneration - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Retinal Degeneration - Products under Development by Companies
Retinal Degeneration - Products under Investigation by Universities/Institutes
Retinal Degeneration - Companies Involved in Therapeutics Development
Alkeus Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Aprogen, Inc.
BBB Therapeutics B.V.
Bionature E.A. Ltd.
Biovista Inc.
GenSight Biologics SA
SanBio, Inc.
Santhera Pharmaceuticals Holding AG
Senju Pharmaceutical Co., Ltd.
Spark Therapeutics, Inc.
Retinal Degeneration - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AP-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BVA-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BVA-203 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Lebers Hereditary Optic Neuropathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Choroideremia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Retinal Degenerative Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Retinoschisin for X-Linked Retinoschisis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
idebenone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MTP-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rAAV2tYFCB-hRS1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SB-623 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule 8 for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Inherited Retinal Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize Neurotrophin Receptor for CNS and Ophthalmological Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SNC-121 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SNJ-1945 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Cancer, Pain, Retinal Degeneration and Niemann-Pick Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retinal Degeneration - Recent Pipeline Updates
Retinal Degeneration - Dormant Projects
Retinal Degeneration - Dormant Projects
Retinal Degeneration - Product Development Milestones
Featured News & Press Releases
Jun 05, 2014: European Medicines Agency Validates Santhera’s Marketing Authorization Application for Raxone in Leber’s Hereditary Optic Neuropathy
May 07, 2014: Santhera Files Marketing Authorization Application in European Union for Raxone in the Treatment of LHON
Mar 04, 2014: Santhera Presents New Efficacy Data from an Expanded Access Program with Raxone for the Treatment of Leber's Hereditary Optic Neuropathy
Jan 21, 2014: Temporary Authorization for Use Granted for Santhera's Raxone for the Treatment of Leber's Hereditary Optic Neuropathy in France
Mar 22, 2013: Santhera Pharma Withdraws Marketing Authorization Application For Raxone In LHON
Jan 18, 2013: Santhera Pharma Receives Negative Opinion From EMA's CHMP On Marketing Authorization Application For Raxone
Nov 16, 2012: Santhera Pharma Expects CHMP Opinion On MAA For Raxone In Early 2013
Jul 26, 2011: Catena Improves Sight For Patients With Inherited Blindness, Newcastle University Study Finds
Jul 22, 2011: EMA Accepts Santhera's Marketing Authorization Application Of Idebenone For Review In LHON
Jun 06, 2011: Santhera Pharma Presents Nonclinical Data In LHON At Joint Congress Of SOE/AAO 2011
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Retinal Degeneration, H1 2015
Number of Products under Development for Retinal Degeneration - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Retinal Degeneration - Pipeline by Alkeus Pharmaceuticals, Inc., H1 2015
Retinal Degeneration - Pipeline by Applied Genetic Technologies Corporation, H1 2015
Retinal Degeneration - Pipeline by Aprogen, Inc., H1 2015
Retinal Degeneration - Pipeline by BBB Therapeutics B.V., H1 2015
Retinal Degeneration - Pipeline by Bionature E.A. Ltd., H1 2015
Retinal Degeneration - Pipeline by Biovista Inc., H1 2015
Retinal Degeneration - Pipeline by GenSight Biologics SA, H1 2015
Retinal Degeneration - Pipeline by SanBio, Inc., H1 2015
Retinal Degeneration - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2015
Retinal Degeneration - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2015
Retinal Degeneration - Pipeline by Spark Therapeutics, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Retinal Degeneration Therapeutics - Recent Pipeline Updates, H1 2015
Retinal Degeneration - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Retinal Degeneration, H1 2015
Number of Products under Development for Retinal Degeneration - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Alkeus Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Aprogen, Inc.
BBB Therapeutics B.V.
Bionature E.A. Ltd.
Biovista Inc.
GenSight Biologics SA
SanBio, Inc.
Santhera Pharmaceuticals Holding AG
Senju Pharmaceutical Co., Ltd.
Spark Therapeutics, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Alcon Incorporated
  • Bausch & Lomb, Inc.
  • Essilor International S.A.
  • Johnson & Johnson Services, Inc.
  • Specsavers Optical Group Ltd.
  • Luxottica Group